HNSN Hansen Medical, Inc. (MM)

Hansen Medical's Sensei(R) X Robotic Catheter System to Be Featured at Heart Rhythm Society's 35th Annual Scientific Sessions

MOUNTAIN VIEW, CA--(Marketwired - May 5, 2014) -  Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced it will exhibit its Sensei® X Robotic Catheter System at the Heart Rhythm Society's (HRS) Annual Scientific Sessions from May 7 - 10 at the Moscone Center in San Francisco, California. Hansen will also reveal its new Sensei X2 Robotic System, which features faster processing, enhanced image integration and a slimmer design. The Sensei X2 is not yet commercially available in the U.S. or Europe. The Company will be conducting product demonstrations and displaying the Sensei Robotic System at Booth 620. 

In addition, the Sensei Robotic System will be featured in poster presentations during the conference. On Friday, May 9 from 9:30 to 10:30am, Antonio Dello Russo, MD, PhD from the Unit of Cardiac Arrhythmia Research Center of Centro Cardiologico Monzino in Milan will present his clinical findings on force sensing with the robotic navigation system in a poster presentation. Later that afternoon, in a poster presentation from 3:30 to 4:30pm, Chintan Trivedi, MD, PhD from St. David's in Austin, TX will discuss his clinical experience with the Sensei X Robotic Catheter System.

"Hansen Medical is pleased to be returning to HRS's Annual Scientific Sessions, one of the year's most important cardiac conferences," said Chris Lowe, Interim CEO of Hansen Medical. "We believe the momentum behind force sensing technology has the potential to offer incremental benefits when coupled with the stability and control of the Sensei System."

About Sensei® X Robotic Catheter System

Through continued advancement of medical robotics, Hansen Medical has developed a next generation minimally-invasive, robotic catheter system, the Sensei X Robotic Catheter System which combines advanced levels of 3D catheter control and 3D visualization. This unique, state of the art technology has been used in over 13,000 patients, and is powered by a robotically controlled arm that allows for catheter navigation, stability and positioning within the patient's heart atria, allowing for the following system advantages:

• Catheter Stability with Force-Sensing
• Instinctive 3D Control
• Reduced Fluoro Time for Physician

About Hansen Medical, Inc. Hansen Medical, Inc., based in Mountain View, California, is a global leader in Intravascular Robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, 9Fr Magellan™ Robotic Catheter, Magellan™ 6Fr Robotic Catheter, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan 9Fr Robotic Catheter has undergone both CE marking and 510(k) clearance and is commercially available in the European Union, and the U.S. The Magellan 6Fr Robotic Catheter has undergone 510(k) clearance in the U.S. and is in limited release for the next several months in anticipation of more wide-scale commercially availability later in 2014. In the European Union, the Company's Sensei® X Robotic Catheter System and Artisan® and Artisan Extend® Control Catheters are cleared for use during electrophysiology (EP) procedures, such as guiding catheters in the treatment of atrial fibrillation (AF), and the Lynx® Robotic Ablation Catheter is cleared for the treatment of AF. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the U.S., the Company's Sensei X Robotic Catheter System and Artisan and Artisan Extend Control Catheters are cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures. In the U.S., the Sensei X Robotic Catheter System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei X Robotic Catheter System and Artisan and Artisan Extend Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF, have not been established. Additional information can be found at www.hansenmedical.com.

Forward-Looking Statements This press release contains forward-looking statements regarding, among other things, statements relating to goals, plans, objectives, milestones and future events. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the uncertain timelines for the sales cycle for newly introduced products; the rate of adoption of our systems and the rate of use of our catheters; the scope and validity of intellectual property rights applicable to our products; competition from other companies; our ability to recruit and retain key personnel; our ability to manage expenses and cash flow, and obtain additional financing; and other risks more fully described in the "Risk Factors" section of our Annual Report on Form 10K for the year ended December 31, 2013 filed with the SEC on March 9, 2014 and the risks discussed in our other reports filed with the SEC. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

"Artisan Extend," "Hansen Medical," "Hansen Medical (with Heart Design)," "Heart Design (Logo)," "Sensei," "Lynx," "Artisan," "Instinctive Motion," "Fine Force Technology," "IntelliSense" are registered trademarks, and "Magellan" and "Hansen Medical Magellan" are trademarks of Hansen Medical, Inc. in the U.S. and other countries.

Investor Contacts: Peter J. Mariani Chief Financial Officer Hansen Medical, Inc. 650.404.5800 Westwicke Partners, LLC. Mark Klausner or Mike Piccinino, CFA 443.213.0500 Email Contact